I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.
The PCN recommends Intravitreal dexamethasone implant (Ozurdex) for the treatment of non-infectious Uveitis in line with NICE TA460
Ozurdex is a payment by results excluded drug and will be considered RED on the traffic light system with treatment being provided by ophthalmology specialist teams in secondary care.
Specialists will be expected to notify commissioners through blueteq by completing tick box proformas for initiation and repeat implants.
